There were rarely no CRS events of grade 3 or higher observed in CD22-ALL, CD30-HL, leY-AML, NKG2D-MM/AML/MDS, and in solid tumor-related CAR-T treatment, including targets of EGFR, GD2, HER2, mesothelin, and TAG-72. This evidence concerns the gene CD22 and Miyoshi myopathy.